Editorial: Advancements in the management of kidney disease and electrolyte derangements.
Editorial: Advancements in the management of kidney disease and electrolyte derangements.
复制标题
社论：肾脏疾病和电解质紊乱治疗的进展。
DOI：
10.1097/mnh.0000000000000823
复制
发表时间：
2022
影响因子：
3.2
通讯作者：
Navaneethan,SankarD
中科院分区：
文献类型：
--
作者：
HollidayJr,MichaelW;Navaneethan,SankarD
随着全球和美国人口平均年龄的增加，慢性肾脏疾病(CKD)的发病率预测是不祥的[1，2]。终末期肾病提供了42-47%的5年生存率，临床实践表明，慢性肾脏病患者的生活质量损失和与慢性肾脏病相关的死亡率的负担显而易见。预计的肾脏护理需求和成本似乎是站不住脚的[3，5]。通过对CKD发病机制、治疗方法和管理质量的基础、翻译和临床研究继续取得进展仍然是前进的道路。在最新一期的《肾脏病与高血压》中，作者回顾了CKD患者护理的新进展。糖尿病肾病(DKD)仍然是CKD的主要原因，并且是预计到2030年终末期肾病(ESKD)患者增加29%-68%的重要因素[2]。尽管指南指导的干预措施包括肾素-血管紧张素-醛固酮系统(RAAS)抑制，DKD相关死亡率正在增加，这与肥胖流行是一致的[6]。Garcia等人(pp.456-463)综述了DKD治疗方面的进展，包括使用钠葡萄糖共转运体-2抑制剂(SGLT-2i)、胰高血糖素样肽1受体激动剂(GLP-1RA)和非类固醇类矿物皮质激素受体拮抗剂(ns-MRA)。SGLT-2抑制剂表现出肾脏特异性地阻断近端小管对尿糖的重吸收，导致葡萄糖尿，并提高肌肉对胰岛素的敏感性，减少肾小球高滤过。除了改善血红蛋白(Hb)A1C外，SGLT-2抑制剂还可以改善患有和不患有慢性肾脏病以及患有和不患有糖尿病的患者的心血管结局、蛋白尿和慢性肾脏病的进展。此外，SGLT-2抑制剂改善了射血分数保留或减少的心力衰竭患者的心血管结局，无论是否合并糖尿病或慢性肾脏病。SGLT-2抑制剂现在是DKD治疗的基石；肾脏疾病：改善全球预后(KDIGO)2020指南建议SGLT-2抑制剂和二甲双胍作为CKD患者的一线治疗药物
Coincident with the increasing average age of the worldwide and US populations, the forecast for chronic kidney disease (CKD) prevalence is ominous [1, 2]. End-stage kidney disease confers 42–47% 5-year survival probability, and clinical practice makes evident the burden of CKD-derived patient loss of quality of life and CKD-related mortality [3, 4]. The projected need and cost for kidney care appears untenable [3, 5]. Continued advancement through basic, translational, and clinical research of CKD pathogenesis, therapeutics and management quality enhancement remains the path forward. In the current issue of Current Opinion in Nephrology and Hypertension authors review novel advances in CKD patient care.Diabetic kidney disease (DKD) remains the leading cause of CKD and is a significant contributor to the projected 29–68% increase in end stage kidney disease (ESKD) patients by 2030 [2]. Despite guideline-directed interventions, including renin–angiotensin–aldosterone system (RAAS) inhibition, DKD-associated mortality is increasing coincident with the obesity epidemic [6]. Therapeutic advances in DKD management are reviewed by Garcia et al.,(pp. 456–463) including use of sodium glucose-cotransporter-2 inhibitors (SGLT-2i), glucagon-like-peptide 1 receptor agonists (GLP-1 RA), and nonsteroidal mineralocorticoid receptor antagonists (ns-MRA). SGLT-2 inhibitors exhibit kidney specific blockade of urine glucose reabsorption in the proximal tubule, resulting in glucosuria and conferring improved insulin sensitivity in muscle and a reduction in glomerular hyperfiltration. In addition to improvement in hemoglobin (Hb) A1C, SGLT-2 inhibitors benefit cardiovascular outcomes, proteinuria, and progression of CKD in patients with and without CKD and with and without diabetes. Further, SGLT-2 inhibitors improved cardiovascular outcomes in heart failure patients with preserved or reduced ejection fraction, with and without diabetes or CKD. SGLT-2 inhibitors are now a cornerstone of DKD management; the Kidney Disease: Improving Global Outcomes (KDIGO) 2020 guidelines recommend SGLT-2 inhibitor along with metformin as the first-line therapy for CKD patients
登录
查看更多内容
影响因子：
3.4
作者：
Li H;Xu J;Bai Y;Zhang S;Cheng M;Jin J
通讯作者：
Jin J
DOI：
10.1053/j.ajkd.2019.06.006
发表时间：
2019-12
期刊：
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子：
--
作者：
Ebele M. Umeukeje;B. Young
通讯作者：
Ebele M. Umeukeje;B. Young
KDIGO 2020 年慢性肾脏病糖尿病管理临床实践指南。
影响因子：
19.6
作者：
I. H. Boer;M. L. Caramori;J. Chan;H. Heerspink;Clint Hurst;K. Khunti;A. Liew;E. Michos;S. Navaneethan;W. Olowu;Tami Sadusky;N. Tandon;K. Tuttle;C. Wanner;K. Wilkens;S. Zoungas;P. Rossing
通讯作者：
P. Rossing
DOI：
10.2147/ijnrd.s294191
发表时间：
2021
影响因子：
2
作者：
Jagannathan R;Rajagopalan K;Hogan J;Hart A;Newell KA;Pastan SO;Patzer RE
通讯作者：
Patzer RE